Pfizer to discontinue Phase III dilated cardiomyopathy trial

Pfizer has announced plans to discontinue the Phase III trial and development programme for PF-07265803 for lamin A/C protein (LMNA)-related dilated cardiomyopathy (DCM).

The latest move is based on data from an interim futility assessment of the Phase III REALM-DCM clinical trial.